semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hematologic Diseases Neutropenia Febrile Neutropenia Sepsis Patient with hematological disease and neutropenia < 500/µl (or < 1000/µl, if criterion 5A is fulfilled) 2. Known or acute infection, or suspected infection, or sepsis, which clinically indicates investigation by blood culture 3. Time-frame after diagnosis or suspicion of infection or sepsis: < 72 hours 4. Species causing infection not known before 5. Patient fulfils criterion A or/and B A. Indication for an initiation of antimicrobial therapy in patients with febrile neutropenia Neutropenia <500/µl or <1000/µl if decline to <500/µl is expected in the next 48h Single (oral) temperature of ≥ 38.3°C, or temperature ≥ 38.0°C lasting for at least 1h or measured twice within 12h No evidence of non-infectious cause of fever (blood products, drugs reactions, etc) B. At least two of the following Temperature >38°C or <36°C Heart rate >90 beats/minute Respiratory rate >20 breaths/minute or PaCO2 <32 mmHg / 4,3 kPa 6. Patient is able to provide written informed consent  Moribund patients with survival expectation < 24h 2. Younger than 18 years 3. Patient is not able to provide informed consent 4. Patients not suitable for study participation in the opinion of investigator
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Meningitis Adults or children whose parent or guardian give consent to participate in the study Adults or children who do not have a serious acute or chronic illness  lack of consent given by an adult or the parent or guardian of a potentially eligible study child Adults or children who have a serious acute or chronic illness
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.5-75.0,  Meningococcemia clinical diagnostic of meningococcal disease  no meningococcal disease
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia, Hemolytic, Autoimmune Age 18 years or over Clinical and biochemical signs of haemolytic anaemia Positive Coombs test with anti-IgG on its own or with anti-CD3d Adequate contraceptive measures (intrauterine device, contraceptive pill or gestagen deposit) for women of childbearing potential  Performance status > 2 Previous treatment with Rituximab Other immune suppressive or anti neoplastic treatment including prednisolone within 3 months Auto immune haemolytic anaemia within 6 months Other serious disease Pregnant women and nursing mothers. Adequate contraceptive measures must be taken for the duration of the study Contraindication for treatment with Rituximab, i.e. patients that develop hypersensitivity/allergy to the contents of the drug or have antibodies against murine proteins Active infection which requires antibiotic treatment
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Sickle Cell Disease Diagnosis of sickle cell disease confirmed through hemoglobin electrophoresis Genotypes SS, SC and Sβ thalassemia Age > 1 year  Liver dysfunction (alanine aminotransferase ALT > 3 times the normal levels Renal dysfunction (creatinine > twice the normal levels) Increase in methemoglobin levels (> 5 times the normal levels) History of recent stroke (< 1 month) and priapism Pregnancy Allergy to L-arginine Use of sildenafil, calcium channel blockers, nitroglycerin or other nitrates
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Platelet Aggregation Defects Patients with common blood disorders such as immune thrombocytopenia purpura(ITP) myelodysplastic syndrome MDS)and myeloproliferative disorders (MPV)  Patients with normal platelet counts
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Chronic Respiratory Failure requiring respiratory support
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Paroxysmal Nocturnal Hemoglobinuria Japanese individuals at least 12 years of age Diagnosis of PNH > 6 months At least one transfusion in the past 2 years for anemia or anemia-related symptoms LDH level ≥ 1.5 x upper limit of normal within 12 weeks Presence of a glycosylphosphatidylinositol (GPI)-deficient red blood cell (RBC) clone (type III cells) by flow cytometry of ≥10% Negative serum pregnancy test for women of child-bearing potential  Platelet count < 30,000/µL Absolute neutrophil count ≤ 500/µL Known or suspected hereditary complement deficiency History of hematopoietic stem cell transplant History of meningococcal disease
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Adult Respiratory Distress Syndrome Acute Lung Injury Adults older than 18 years of age, admitted to the ICU with one or more of the following risk factors for ARDS/ALI Sepsis, defined as the presence of infection-related systemic inflammatory response syndrome (SIRS). SIRS is defined as the presence of two or more of the following Temperature >38.5ºC or <35ºC Heart rate >90 beats/min Respiratory rate >20 breaths/min or PaCO2 <32 mmHg WBC >12,000 cells/mm3, <4000 cells/mm3, or >10 percent immature (band) forms Pneumonia, including community and health care associated pneumonias Aspiration, defined as the witnessed inhalation of gastric contents Acute pancreatitis Bilateral lung contusion  Patients already on a statin Current indication for statin therapy according to the National guidelines NPO order Active liver disease, defined as ALT or AST > 3 times the upper limits of normal History of myopathy History of uncontrolled seizure disorder Pregnancy or breastfeeding Immunosuppressive therapy, including prednisone at dose > 10 mg/day Preexistent lung disease indicated by history or chest film High risk for cardiogenic pulmonary edema (defined as the presence of ventricular fibrillation, acute myocardial infarction, congestive heart failure with EF < 40%)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dense Deposit Disease Membranoproliferative Glomerulonephritis Adult patients with biopsy proven DDD or C3 nephropathy, at least 18 years of age hour urine protein > 1000 mg/day, urine protein:creatinine ratio > 1.0, or acute renal failure (defined as > 50% increase in serum creatinine from baseline) Willing and able to sign informed consent Patients of childbearing age must agree to use birth control Patients must be willing to be vaccinated against meningococcal disease or have documentation of previous vaccination against meningococcal disease  Patients under 18 years of age Patients unable to sign informed consent Patients having received rituximab or another monoclonal antibody within 6 months of the trial Patients currently taking and unable to discontinue other immunomodulatory therapies (e.g. cyclosporine, high-dose steroids, mycophenolate mofetil) unless these other therapies are indicated for prophylaxis of transplant rejection (e.g. stable doses of mycophenolate mofetil and/or calcineurin inhibitor). Patients on chronic steroid therapy who are unable to taper down to <10 mg/day will be excluded Patients of childbearing age who refuse to use birth control Patients with a baseline estimated GFR less than 30 ml/min/1.73m2 Patients with other renal diseases (e.g. diabetic nephropathy, renal vascular disease) that would interfere with interpretation of the study Patients with comorbid conditions that would interfere with completion of the trial (malignancies, congestive heart failure (CHF), recent myocardial infarction) Patients with known contraindications to the use of eculizumab, including refusal to receive N. meningitides vaccine prior to therapy
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Hemoglobinuria, Paroxysmal Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry data  Patients have no Flow cytometry data
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Respiratory Distress Syndrome Acute Renal Failure Acute Respiratory Distress Syndrome according to the AECC definition Acute Renal Failure according to the RIFLE definition  Age < 18 years PaO2/FiO2 < 100 with FIO2 = 1 and PEEP > 18 cmH2O DNR order or death expected within the next 3 days Intracranial haemorrhage or hypertension Heparin allergy
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Severe Sepsis Severe sepsis which were defined by the ACCP/SCCM consensus conference  Post CPR, pregnant and under 16 years old patients
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.5-18.0,  Shiga Toxin Producing Bacterial Infection Bloody diarrhea (by visual inspection) for no more than 36 hours prior to screening (signature of the informed consent). 2. Detection of Shiga toxin (Stx1 and/or Stx2) in stool  Laboratory findings compatible with development of at least two out of three following that define Hemolytic Uremic Syndrome (HUS): Hemolytic Anemia: hematocrit < 30% with evidence of hemolysis (as indicated by Lactate Dehydrogenase (LDH) above the upper limit of normal for age or the finding of schistocytes on peripheral smear); Thrombocytopenia: platelet count <150 x 103/uL; Nephropathy: serum creatinine > Upper Limit Normal (ULN) adjusted for age and gender. 2. Bloody-diarrhea suspected not to be caused by Shiga Toxin-Producing Bacteria (STPB) but by other organisms or preexisting diseases. 3. Family history of proven or suspected hereditary Hemolytic Uremic Syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP). 4. History of chronic/recurrent hemolytic anemia or thrombocytopenia
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Thrombotic Thrombocytopenic Purpura Congenital Thrombotic Thrombocytopenic Purpura Familial Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura, Congenital Upshaw-Schulman Syndrome Severe deficiency ( ≤ 10% activity) and no 13 inhibitor on two or more occasions at least one month apart Being a family member of a confirmed or suspected patient Molecular analysis of gene with one or more mutations and/or positive infusion trial (full recovered activity after infused fresh frozen plasma (FFP) with a plasma half-life of 2-4 days)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Subclavian Steal patients who revealed subclavian steal in the duplex study  patients who has vascular access in the arm instead of the forearm
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Kidney Replacement Disorder Age > 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy  Age < 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study